newsfilter
← Latest News
Business Wire·

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NH

EL SEGUNDO, Calif. & SAN ANTONIO, Texas--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. NantHealth’s presentation demonstrated that the adoption of trastuzumab biosimilars does not appear to be affected by patient selection, stage of disease, or goals of care.